Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Immatics N.V. - Ordinary Shares
(NQ:
IMTX
)
9.705
+0.325 (+3.46%)
Streaming Delayed Price
Updated: 10:56 AM EST, Jan 14, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immatics N.V. - Ordinary Shares
< Previous
1
2
3
4
Next >
Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress
December 11, 2025
From
https://immatics.com/
Via
GlobeNewswire
Immatics Announces $125 Million Underwritten Offering
December 05, 2025
From
https://immatics.com/
Via
GlobeNewswire
Immatics Announces Third Quarter 2025 Financial Results and Business Update
November 17, 2025
From
https://immatics.com/
Via
GlobeNewswire
Immatics Appoints Amie Krause as Chief People Officer
October 27, 2025
From
https://immatics.com/
Via
GlobeNewswire
Immatics Appoints Venkat Ramanan as Chief Financial Officer
October 01, 2025
From
https://immatics.com/
Via
GlobeNewswire
Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps
November 12, 2025
From
https://immatics.com/
Via
GlobeNewswire
Adaptimmune Plunges After Announcing Nasdaq Delisting Amidst Compliance Failures and Cost-Cutting Measures
October 20, 2025
Adaptimmune Therapeutics plc (NASDAQ: ADAP) has sent shockwaves through the biotechnology sector with its announcement on October 20, 2025, of a voluntary delisting of its American Depositary Shares...
Via
MarketMinute
Topics
Initial Public Offering
Regulatory Compliance
Workforce
Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium
October 20, 2025
From
https://immatics.com/
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
↗
October 10, 2025
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
October 02, 2025
Via
Benzinga
Fabrinet, Adecoagro And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
↗
August 19, 2025
Via
Benzinga
Immatics Announces Second Quarter 2025 Financial Results and Business Update
August 13, 2025
From
https://immatics.com/
Via
GlobeNewswire
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
May 31, 2025
From
https://immatics.com/
Via
GlobeNewswire
Immatics Announces First Quarter 2025 Financial Results and Business Update
May 13, 2025
From
https://immatics.com/
Via
GlobeNewswire
Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting
April 23, 2025
From
https://immatics.com/
Via
GlobeNewswire
Immatics Announces Full Year 2024 Financial Results and Business Update
March 27, 2025
From
https://immatics.com/
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
January 03, 2025
Via
Benzinga
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
November 18, 2024
From
https://immatics.com/
Via
GlobeNewswire
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
November 08, 2024
From
https://immatics.com/
Via
GlobeNewswire
Immatics Announces Pricing of $150 Million Public Offering
October 10, 2024
From
https://immatics.com/
Via
GlobeNewswire
Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday?
↗
October 10, 2024
Immatics announced updated Phase 1b data for its IMA203 therapy in metastatic melanoma. A deep tumor reduction response was observed in about half of the patients, with positive survival benefits...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
October 10, 2024
Via
Benzinga
Immatics Announces Proposed $150 Million Public Offering
October 10, 2024
From
https://immatics.com/
Via
GlobeNewswire
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial
October 10, 2024
From
https://immatics.com/
Via
GlobeNewswire
Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024
October 04, 2024
From
https://immatics.com/
Via
GlobeNewswire
Biotech Stocks : Are You A Trader Or A Longer Term Investor?
↗
October 01, 2024
Biotech bull market is intact as indicated by large cap biopharma and the best performing funds.
Via
Talk Markets
Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update
September 16, 2024
From
https://immatics.com/
Via
GlobeNewswire
Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024
September 06, 2024
From
https://immatics.com/
Via
GlobeNewswire
IMTX Stock Earnings: Immatics Beats EPS, Beats Revenue for Q2 2024
↗
August 13, 2024
IMTX stock results show that Immatics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Immatics Announces Second Quarter 2024 Financial Results and Business Update
August 13, 2024
From
https://immatics.com/
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
